Media coverage about Axovant Sciences (NYSE:AXON) has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Axovant Sciences earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.8046866927329 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news stories that may have impacted Accern’s analysis:

Several equities research analysts recently commented on the company. Chardan Capital reissued a “sell” rating and set a $3.00 target price on shares of Axovant Sciences in a report on Saturday, September 23rd. BidaskClub raised Axovant Sciences from a “strong sell” rating to a “sell” rating in a report on Saturday, September 23rd. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $30.00 target price on shares of Axovant Sciences in a report on Monday, September 25th. UBS AG cut Axovant Sciences from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 26th. Finally, Piper Jaffray Companies cut Axovant Sciences from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $32.00 to $9.00 in a report on Tuesday, September 26th. Three analysts have rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $14.13.

Axovant Sciences (NYSE AXON) traded down 2.97% on Wednesday, hitting $6.54. The company’s stock had a trading volume of 2,498,241 shares. The company’s market capitalization is $703.21 million. The company has a 50 day moving average price of $14.97 and a 200-day moving average price of $14.97. Axovant Sciences has a 1-year low of $6.13 and a 1-year high of $27.98.

Axovant Sciences (NYSE:AXON) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12). On average, equities analysts forecast that Axovant Sciences will post ($2.02) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Axovant Sciences (AXON) Receiving Somewhat Favorable Press Coverage, Analysis Shows” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Insider Buying and Selling by Quarter for Axovant Sciences (NYSE:AXON)

Receive News & Stock Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related stocks with our FREE daily email newsletter.